As COVID Wanes, Tuberculosis Deaths Must Become Visible
Tuberculosis has killed 1,5 million people in 2020 - mostly in African and Asian countries - while two million people died of COVID-19 worldwide during the same period. Credit: Athar Parvaiz/IPSBy Angelique Luabeya Kany KanyCAPE TOWN, South Africa, May 19 2022 (IPS) It is time to treat the scourge of Tuberculosis scourge with the same urgency as we did the COVID-19 pandemic. As we emerge from the devastating toll of the pandemic on people’s lives and on global economies, we must wake up to face the staggering toll of 1.5 million Tuberculosis deaths and 10 million new infections recorded in 2020. And these deaths wer...
Source: IPS Inter Press Service - Health - May 19, 2022 Category: International Medicine & Public Health Authors: Angelique Luabeya Kany Kany Tags: Africa Headlines Health Poverty & SDGs TerraViva United Nations tuberculosis Source Type: news

Serum Institute seeks emergency use authorisation for its rBCG tuberculosis vaccine
The EUA application was submitted on March 22 by Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII). India's TB immunisation programme currently offers BCG vaccination at birth or as early as possible till one year of age. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 27, 2022 Category: Pharmaceuticals Source Type: news

South Africa: It Is Time to Invest in Ending TB in SA
[spotlight] Each year the global community commemorates World TB Day on 24 March. On this day, 140 years ago, Robert Koch discovered the bacillus that causes tuberculosis. Amazingly, the Bacillus Calmette Guerin (BCG) vaccine, still used routinely, was first injected into a human in 1921 - 101 years ago. TB is an old disease - it was discovered in Egyptian mummies dating back to 600 BC. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - March 23, 2022 Category: Infectious Diseases Source Type: news

Bharat Biotech enters into partnership with Biofabri for TB vaccine
The new TB vaccine, 'MTBVAC', is being manufactured and developed by Biofabri, in close collaboration with the University of Zaragoza, IAVI and the Tuberculosis Vaccine Initiative (TBVI). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 16, 2022 Category: Pharmaceuticals Source Type: news

Africa: Good and Bad News About New TB Vaccines
[spotlight] The tuberculosis (TB) vaccine pipeline is depleted with little progress of candidate vaccines through the pipeline in the last few years. This is creating a serious problem for the next decade of vaccine development, warns Professor Mark Hatherill, director of the South African Tuberculosis Vaccine Initiative (SATVI). (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - March 1, 2022 Category: Infectious Diseases Source Type: news

Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022
This report describes a recommendation for using a 4-month regimen for the treatment of drug-susceptible pulmonary tuberculosis. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - February 24, 2022 Category: American Health Tags: Healthy Living MMWR Morbidity & Mortality Weekly Report Tuberculosis (TB) Tuberculosis Vaccine (BCG) Source Type: news

South Africa: Model of New TB Vaccine Shows Its Potential Impact and Value in South Africa and India
[The Conversation Africa] Two years of battling COVID-19 has been bad news for tuberculosis (TB) programmes. Respiratory clinicians and researchers have had their time and focus directed elsewhere. And TB has taken advantage. In 2021, the number of TB deaths rose for the first time in over a decade. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 9, 2022 Category: African Health Source Type: news

Underfunded and Deadly Tuberculosis Needs its Own Bill Gates
Community support workers are key in raising awareness about TB and promoting diagnosis and treatment. Credit, Busani Bafana/IPS By Busani BafanaBULAWAYO, Zimbabwe, Jan 7 2022 (IPS) Global efforts to end tuberculosis (TB) are futile without dedicated investment in research into the debilitating disease that is killing 4000 people a day, Stop TB Partnership warns. “TB is a disease that is not a darling of donors and investors,” Lucica Ditiu, the Executive Director of the Stop TB Partnership, told IPS in an interview from Geneva. “We do not have a Bill Gates that can support TB research, yet TB remains a disease of con...
Source: IPS Inter Press Service - Health - January 7, 2022 Category: International Medicine & Public Health Authors: Busani Bafana Tags: Africa COVID-19 Development & Aid Featured Headlines Health Human Rights Humanitarian Emergencies TerraViva United Nations ​ #ZImbabwe #HIV/Aids IPS UN Bureau TB tuberculosis Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Call for action on TB as deaths rise for first time in decade
Tuberculosis campaigners tell G20 leaders $1bn is needed annually for vaccine research to reverse decades of underfundingA group of tuberculosis survivors are calling for more funding and action to find new vaccines, after the numbers dying of the infection rose for the first time in 10 years.In 2020,1.5 million were killed by TB and 10 million infected, according to the World Health Organization. Campaigners want world leaders to invest $1bn ( £730m) every year into vaccine research, spurred on by the momentum from the Covid jab development.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 28, 2021 Category: Science Authors: Kaamil Ahmed Tags: Global development Tuberculosis Vaccines and immunisation Health Society Inequality World Health Organization Medical research Epidemics World news G20 Science Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

South Africa: UCT's Dr Virginie Rozot Awarded Wellcome Leap Grant for TB Research
[UCT] The University of Cape Town's (UCT) Dr Virginie Rozot, a research officer at the South African Tuberculosis Vaccine Initiative (SATVI), has been awarded a multi?year contract as part of Wellcome Leap's Delta Tissue (?T) programme. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 31, 2021 Category: African Health Source Type: news

Why Is the TB Vaccine Not Given in the US
Why Is the TB Vaccine Not Given in the U.S.? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 30, 2021 Category: General Medicine Source Type: news